Vertex Pharmaceuticals announces positive results from Phase 2 trials of its new, first-in-class non-opioid pain medication VX 548. The oral pain medicine has the potential to revolutionize pain management, offering an alternative to opioids. Vertex plans to proceed with Phase 3 trials and will host a conference call to discuss the results. Investors and healthcare professionals should stay tuned for updates on VX 548.